Vincere Biosciences develops novel therapeutics targeting Parkinson's disease and age-related kidney disease, utilizing proprietary AI/ML tools to design and optimize drug candidates. Backed by over $2.7 million in grants from organizations like the NIH and the Michael J. Fox Foundation, the company aims to initiate human trials for its first molecule within 18 months.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DPHBFounders
Product
Problem
Parkinson's disease and age-related kidney disease lack effective treatments, creating a need for novel therapeutics to address these debilitating conditions. Current drug discovery methods can be slow and inefficient, hindering the development of new medicines.
Solution
Vincere Biosciences is developing new medicines for age-related diseases, including Parkinson’s and kidney disease, by leveraging artificial intelligence and machine learning (AI/ML) to accelerate drug discovery. Their proprietary AI/ML tools enable the design and optimization of drug candidates with improved efficacy and safety profiles. This approach allows for the rapid generation and screening of a large number of molecules, identifying promising candidates for further development. Vincere Biosciences aims to advance its lead molecule into human clinical trials, offering a potential breakthrough in the treatment of these diseases.
Target Audience
The primary target audience includes patients suffering from Parkinson's disease and age-related kidney disease, as well as pharmaceutical companies seeking novel therapeutic candidates for these conditions.
Features
- Proprietary AI/ML platform for drug design and optimization
- Focus on developing therapeutics for Parkinson's disease and age-related kidney disease
- Portfolio of over 1000 molecules protected by over 20 global patents
- Lead molecule poised to enter human clinical trials